-
公开(公告)号:EP1913014A1
公开(公告)日:2008-04-23
申请号:EP06764263.7
申请日:2006-07-28
发明人: DE KOCK, Herman, Augustinus , RABOISSON, Pierre, Jean-Marie, Bernard , SIMMEN, Kenneth, Alan , LINDSTRÖM, Mats Stefan , KAHNBERG, Pia Cecilia , ANTONOV, Dmitry , NILSSON, Karl Magnus , SAMUELSSON, Bengt Bertil , ROSENQUIST, Åsa Annica, Kristina
IPC分类号: C07K5/078 , A61K31/4709 , A61P31/14 , C07K5/06
CPC分类号: A61K31/4709 , C07K5/06165 , Y02A50/385 , Y02A50/387
摘要: Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要翻译: 式(I)的HCV抑制剂及其N-氧化物,盐和立体异构体,其中虚线代表原子C7和C8之间的任选双键; R1是氢或C1-6烷基; R2是氢或C1-6烷基; 并且n是3,4,5或6; 提供了含有化合物(I)的药物组合物和用于制备化合物(I)的方法。 还提供了式(I)的HCV抑制剂与利托那韦的生物可用组合。
-
公开(公告)号:EP1912981A2
公开(公告)日:2008-04-23
申请号:EP06764268.6
申请日:2006-07-28
发明人: RABOISSON, Pierre, Jean-Marie, Bernard , DE KOCK, Herman, Augustinus , HU, Lili , SIMMEN, Kenneth, Alan , LINDQUIST, Karin Charlotta , LINDSTRÖM, Mats Stefan , BELFRAGE, Anna Karin Gertrud Linnea , WÄHLING, Horst Jürgen , NILSSON, Karl Magnus , SAMUELSSON, Bengt Bertil , ROSENQUIST, Åsa Annica Kristina , SAHLBERG, Sven Crister , WALLBERG, Hans, Kristian , KAHNBERG, Pia, Cecilia , CLASSON, Björn, Olof
IPC分类号: C07D417/04
CPC分类号: C07D487/10 , C07D245/04
摘要: Compounds of the formula (I), and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(=O)PR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; ---- deonotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl- carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
摘要翻译: 式(I)化合物及其N-氧化物,盐和立体异构体,其中A是OR1,NHS(= O)PR2; 其中; R 1是氢,C 1 -C 6烷基,C 0 -C 3亚烷基碳环基,C 0 -C 3亚烷基 - 杂环基; R 2是C 1 -C 6烷基,C 0 -C 3亚烷基碳环基,C 0 -C 3亚烷基杂环基; p独立地为1或2; n是3,4,5或6; ----定义一个可选的双键; L是N或CRz; Rz是H或与星号碳形成双键; Rq是H或当L是CRz时,Rq也可以是C1-C6烷基; 任选被一个或两个或三个各自独立地选自C 1 -C 6烷基,C 1 -C 6烷氧基,羟基,卤素,卤代C 1 -C 6烷基,氨基,单或二烷基氨基,单或二烷基氨基羰基,C 1 -C 6烷基 - 羰基氨基 C 0 -C 3亚烷基碳环基和C 0 -C 3亚烷基杂环基; R5是氢,C1-C6烷基,C1-C6烷氧基C1-C6烷基或C3-C7环烷基; R 6为氢,C 1 -C 6烷基,C 1 -C 6烷氧基,C 0 -C 3亚烷基碳环基,C 0 -C 3亚烷基杂环基,羟基,溴,氯或氟可用于治疗或预防诸如HCV的黄病毒感染。
-
公开(公告)号:EP1912981B1
公开(公告)日:2010-01-20
申请号:EP06764268.6
申请日:2006-07-28
发明人: RABOISSON, Pierre, Jean-Marie, Bernard , DE KOCK, Herman, Augustinus , HU, Lili , SIMMEN, Kenneth, Alan , LINDQUIST, Karin Charlotta , LINDSTRÖM, Mats Stefan , BELFRAGE, Anna Karin Gertrud Linnea , WÄHLING, Horst Jürgen , NILSSON, Karl Magnus , SAMUELSSON, Bengt Bertil , ROSENQUIST, Åsa Annica Kristina , SAHLBERG, Sven Crister , WALLBERG, Hans, Kristian , KAHNBERG, Pia, Cecilia , CLASSON, Björn, Olof
IPC分类号: C07D417/04
CPC分类号: C07D487/10 , C07D245/04
摘要: Compounds of the formula (I), and N-oxides, salts, and stereoisomers thereof wherein A is OR1, NHS(=O)PR2; wherein; R1 is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl; R2 is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl; p is independently 1 or 2; n is 3, 4, 5 or 6; ---- deonotes an optional double bond; L is N or CRz; Rz is H or forms a double bond with the asterisked carbon; Rq is H or when L is CRz, Rq can also be C1-C6alkyl; Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6 alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl- carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3 alkyleneheterocyclyl; R5 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl; R6 is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.
-
公开(公告)号:EP1913014B1
公开(公告)日:2011-01-26
申请号:EP06764263.7
申请日:2006-07-28
发明人: DE KOCK, Herman, Augustinus , RABOISSON, Pierre, Jean-Marie, Bernard , SIMMEN, Kenneth, Alan , LINDSTRÖM, Mats Stefan , KAHNBERG, Pia Cecilia , ANTONOV, Dmitry , NILSSON, Karl Magnus , SAMUELSSON, Bengt Bertil , ROSENQUIST, Åsa Annica, Kristina
IPC分类号: C07K5/078 , A61K31/4709 , A61P31/14 , C07K5/06
CPC分类号: A61K31/4709 , C07K5/06165 , Y02A50/385 , Y02A50/387
摘要: Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R1 is hydrogen or C1-6alkyl; R2 is hydrogen or C1-6alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
-
-
-